EGM
ACAD icon

Engineers Gate Manager’s Acadia Pharmaceuticals ACAD Stock Holding History

Engineers Gate Manager’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,032
Closed -$1.47M – 2196
2026
Q1 		$1.47M Sell
66,032
-7,808
-11% -$187K 0.02% 861
2025
Q4 		$1.97M Buy
73,840
+14,319
+24% +$342K 0.02% 713
2025
Q3 		$1.27M Buy
59,521
+19,376
+48% +$458K 0.01% 1026
2025
Q2 		$866K Sell
40,145
-58,759
-59% -$1.09M 0.01% 1192
2025
Q1 		$1.64M Sell
98,904
-1,044
-1% -$19K 0.03% 784
2024
Q4 		$1.83M Sell
99,948
-33,246
-25% -$537K 0.03% 665
2024
Q3 		$2.05M Buy
133,194
+25,449
+24% +$425K 0.04% 645
2024
Q2 		$1.75M Sell
107,745
-96,928
-47% -$1.56M 0.04% 616
2024
Q1 		$3.78M Buy
+204,673
New +$5.07M 0.1% 265
2023
Q4 		– Sell
-142,241
Closed -$2.96M – 1935
2023
Q3 		$2.96M Buy
142,241
+76,880
+118% +$2.09M 0.11% 241
2023
Q2 		$1.57M Sell
65,361
-11,249
-15% -$250K 0.06% 455
2023
Q1 		$1.44M Buy
76,610
+57,530
+302% +$1.1M 0.06% 430
2022
Q4 		$304K Sell
19,080
-16,175
-46% -$253K 0.02% 1179
2022
Q3 		$577K Buy
35,255
+2,568
+8% +$41.6K 0.04% 705
2022
Q2 		$461K Buy
+32,687
New +$610K 0.02% 1154
2022
Q1 		– Sell
-24,319
Closed -$568K – 1791
2021
Q4 		$568K Buy
+24,319
New +$489K 0.03% 966
2021
Q3 		– Sell
-11,030
Closed -$269K – 1590
2021
Q2 		$269K Sell
11,030
-29,845
-73% -$674K 0.02% 1204
2021
Q1 		$1.05M Buy
40,875
+32,425
+384% +$1.43M 0.05% 565
2020
Q4 		$452K Sell
8,450
-41,790
-83% -$2.07M 0.02% 1040
2020
Q3 		$2.07M Buy
50,240
+33,688
+204% +$1.45M 0.1% 286
2020
Q2 		$802K Buy
+16,552
New +$795K 0.04% 699
2020
Q1 		– Sell
-18,151
Closed -$776K – 1525
2019
Q4 		$776K Buy
+18,151
New +$790K 0.03% 775
2019
Q3 		– Sell
-22,550
Closed -$603K – 1342
2019
Q2 		$603K Buy
+22,550
New +$576K 0.03% 658

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Engineers Gate Manager's ACAD Position: Q2 2026 in Review

Engineers Gate Manager sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 66,032 shares — an estimated $1.47M sold.

Engineers Gate Manager first reported a position in ACAD in Q2 2019 and held it in 23 quarters. The position peaked at $3.78M in Q1 2024. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Engineers Gate Manager reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 66,032 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.47M.
  • Engineers Gate Manager first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 23 quarters.
  • Engineers Gate Manager's Acadia Pharmaceuticals position peaked at $3.78M in Q1 2024.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.